Takeda’s Adcetris (brentuximab vedotin) + AVD Receives EU Approval for CD30+ Stage IV Hodgkin Lymphoma (HL) in Adults

 Takeda’s Adcetris (brentuximab vedotin) + AVD Receives EU Approval for CD30+ Stage IV Hodgkin Lymphoma (HL) in Adults

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

 Shots:

  • The approval is based on P-III ECHELON-1 study result assessing Adcetris + AVD (adriamycin, vinblastine and dacarbazine) vs ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) in patients with previously untreated CD30-positive and has met its 1EPs with 23% reduction in risk progression & improvement in PFS
  • According to 2009 deal b/w Seattle Genetics & Takeda for Adcetris ((SGN-35), Seattle to receive $30M milestone on Adcetris’ EU approval and has commercialization rights in the US and Canada. Takeda to get WW commercialization rights for Adcetris (Ex-the US & Canada)
  • ADCETRIS, IV is an antibody-drug conjugate (ADC) with anti-CD30 mAb and has received the US FDA approval for 6 indications, Health Canada approval for r/r Hodgkin Lymphoma and sALCL in 2013 & marketed in 70 countries

Click here, Click here, to read full press release/ article | Ref: Takeda, Seattle Genetics | Image: Delveinsight

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post